Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
4 results loaded, newest first. End of these results.
AstraZeneca Plc said the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) recommended Enhertu for approval as adjuvant treatment for HER2-positive early breast cancer.
AstraZeneca said its breast cancer therapy Enhertu has been recommended for approval by EU regulators for early breast cancer.
AstraZeneca and Daiichi Sankyo's Enhertu has been recommended for approval in the EU as a treatment for adult patients with resected HER2-positive breast cancer who have residual disease after neoadjuvant treatment. The CHMP based its opinion on the DESTINY-Breast05 trial, which showed Enhertu reduced the risk of invas
HUTCHMED (China) (NASDAQ: HCM ) released quarterly financial results and hosted an earnings call on Thursday. Read the complete transcript below. This transcript is brought to you APIs. For real-time access to our entire catalog, please visit for a consultation. The full earnings call is available at Summary HUTCHMED (